-+ 0.00%
-+ 0.00%
-+ 0.00%

RATIO THERAPEUTICS HAS SUCCESSFULLY DOSED THE FIRST COHORT IN ITS PHASE 1/2 STUDY EVALUATING A NOVEL FAP-TARGETED RADIOPHARMACEUTICAL IN PATIENTS WITH LATE-STAGE AGGRESSIVE SARCOMAS

Reuters·12/16/2025 13:03:22

Please log in to view news